FDAnews
www.fdanews.com/articles/85266-medicis-pharmaceutical-corp-is-moving-higher-on-reloxin-news

MEDICIS PHARMACEUTICAL CORP. IS MOVING HIGHER ON RELOXIN NEWS

March 14, 2006

Ipsen announced after the close on Monday that it will grant Aesthetica Ltd., a wholly owned subsidiary of Medicis Pharmaceutical Corp. (MRX | charts | news | Powerrating), rights to develop, distribute and commercialize Ipsen's botulinum toxin product in the U.S., Canada and Japan for aesthetic use by physicians. The product is commonly referred to as Reloxin in the U.S. market and Dysport outside the U.S.
TradingMarkets.com